Abstract 1189
Background
Venous thromboembolism (VTE) is frequently observed in patients with solid tumor. Previous report suggested that the prevalence of VTE varied among different ethnic groups. The objectives of this prospective observational study are to estimate the prevalence of VTE in Japanese patients with advanced solid tumor based on intensive screening, using CT scans, lower-extremity ultrasonography, and D-dimer testing.
Methods
Eight-hundred sixty Japanese patients were enrolled into this study. Adult (age ≥20 years) patients with metastatic or locally advanced solid tumor without anticoagulant therapy, who are planning to receive chemotherapy during 4 weeks, PS 0-2 were eligible in this study. Evaluations of VTE were performed at enrollment, 12 and 24 weeks. Primary endpoint was the prevalence of VTE for 24 weeks, and secondary endpoints included the incidence of VTE (at enrollment, 12 weeks, 24 weeks), VTE for 24 weeks by primary cancer site, symptomatic VTE for 24 weeks, pulmonary thromboembolism (PE), treatment of VTE.
Results
The median age was 68 years (range 28-96 years), 34% female, 46/45/8% performance status 0/1/2. Primary cancer site included lung (71%), gastrointestinal (GI) (15%), hepatobiliary and pancreatic (HP) (5%), and gynecological (3%). The prevalence of VTE for 24 weeks was 22.6% (95%CI: 19.8-25.5%). The incidences of VTE were 11.3% (97/858) at enrollment, 16.8% (134/799) at 12 weeks, 14.1% (101/716) at 24 weeks. Among 761 patients without VTE at enrollment, 97 (12.7%) showed VTE after the start of chemotherapy. The prevalence of VTE for 24 weeks was 24.1% in patients with lung, 17.7% with GI, 25.6% with HP, and 32.1% in gynecological cancer. Symptomatic VTE for 24 weeks was observed in 4.0%, and PE was in 1.0%. Treatment of anticoagulant for VTE was started in 15.0% (129/858) after enrollment in this study.
Conclusions
This prospective observational study showed that prevalence of VTE was relatively high in Japanese patients with advanced solid tumor under intensive screening, compared with previous reports. Although most of patients with VTE were asymptomatic, prophylactic anticoagulant therapies may be considered in this study population.
Clinical trial identification
UMIN000015243.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5128 - IO-Synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany
Presenter: Adrien Dixmier
Session: Poster Display session 1
Resources:
Abstract
2066 - Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first line (1L) immuno-oncology (IO) monotherapy (mono tx)
Presenter: Denis Talbot
Session: Poster Display session 1
Resources:
Abstract
5919 - Real-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States
Presenter: David Stenehjem
Session: Poster Display session 1
Resources:
Abstract
3368 - Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
Presenter: Nikolaj Frost
Session: Poster Display session 1
Resources:
Abstract
3775 - Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
3926 - Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: a REAL-Oncology analysis from the I-O Optimise initiative
Presenter: Michael Snee
Session: Poster Display session 1
Resources:
Abstract
5068 - First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Presenter: Karim Amrane
Session: Poster Display session 1
Resources:
Abstract
1182 - Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small-cell lung cancer patients
Presenter: Teppei Sugano
Session: Poster Display session 1
Resources:
Abstract
2297 - Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Presenter: Yosuke Kawashima
Session: Poster Display session 1
Resources:
Abstract
2739 - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Presenter: Christian Grohe
Session: Poster Display session 1
Resources:
Abstract